International Journal of Clinical Research

Objective To explore the clinical effect of Orlistat combined with Metformin in the treatment of obese polycystic ovary syndrome. Methods 74 patients with obese polycystic ovary syndrome admitted to our hospital from January 2022 to January 2023 were selected and randomly divided into a control group and an observation group, with 37 patients in each group. The control group was treated with Orlistat, and the observation group was treated with Orlistat combined with Metformin. Compare the body mass index, insulin resistance index (Home-IR), pregnancy rate, preterm birth rate, and miscarriage rate of two groups of patients before and after treatment. Results After treatment, the improvement of body mass index, Home-IR index, and serum sex hormone levels in the observation group were better than those in the control group, with statistically significant differences (P<0.05); The pregnancy rate of the observation group was higher than that of the control group, while the premature birth rate and miscarriage rate were lower than those of the control group, with statistically significant differences (P<0.05). Conclusion Orlistat combined with Metformin has a significant clinical effect in the treatment of obese polycystic ovary syndrome, which can significantly improve the insulin resistance status of patients and improve the pregnancy outcome, and is worthy of clinical promotion.

Orlistat; Metformin; Obese polycystic ovary syndrome